UB Paderborn / Katalog / Suche / in CDI

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Clinical pharmacokinetics, 2014-01, Vol.53 (1), p.1-16

2014

Volltextzugriff (PDF)

The effect of food on the absorption and pharmacokinetics of rivaroxaban

International journal of clinical pharmacology and therapeutics, 2013-07, Vol.51 (7), p.549

2013

Volltextzugriff (PDF)

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

Journal of clinical pharmacology, 2013-03, Vol.53 (3), p.249-255

2013

Volltextzugriff (PDF)

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

Journal of clinical pharmacology, 2007-02, Vol.47 (2), p.218-226

2007

Volltextzugriff (PDF)

Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial

Nephrology, dialysis, transplantation, 2021-12, Vol.36 (12), p.2263-2273

2021

Volltextzugriff (PDF)

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Current medical research and opinion, 2008-10, Vol.24 (10), p.2757-2765

2008

Volltextzugriff (PDF)

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Journal of clinical pharmacology, 2006-05, Vol.46 (5), p.549-558

2006

Volltextzugriff (PDF)

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

British journal of clinical pharmacology, 2010-11, Vol.70 (5), p.703-712

2010

Volltextzugriff (PDF)

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 : an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects

European journal of clinical pharmacology, 2005-12, Vol.61 (12), p.873-880

2005

Volltextzugriff (PDF)

Serum markers detect the presence of liver fibrosis: A cohort study

Gastroenterology (New York, N.Y. 1943), 2004-12, Vol.127 (6), p.1704-1713

2004

Volltextzugriff (PDF)

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

British journal of clinical pharmacology, 2013-09, Vol.76 (3), p.455-466

2013

Volltextzugriff (PDF)

Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers

British journal of clinical pharmacology, 2018-05, Vol.84 (5), p.865-875

2018

Volltextzugriff (PDF)

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study

Thrombosis journal, 2018-12, Vol.16 (1), p.31-13, Article 31

2018

Volltextzugriff (PDF)

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation

Drug safety, 2008, Vol.31 (1), p.67-77

2008

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers

Clinical pharmacology in drug development, 2019-05, Vol.8 (4), p.467-479

2019

Volltextzugriff (PDF)

Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects

Clinical pharmacology in drug development, 2013-07, Vol.2 (3), p.270-277

2013

Volltextzugriff (PDF)

Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study

Pharmaceuticals (Basel, Switzerland), 2012-02, Vol.5 (3), p.279-296

2012

Volltextzugriff (PDF)

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

British journal of clinical pharmacology, 2013-07, Vol.76 (1), p.89-98

2013

Volltextzugriff (PDF)

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Clinical pharmacology and therapeutics, 2005-10, Vol.78 (4), p.412-421

2005

Volltextzugriff (PDF)

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Blood, 2019-11, Vol.134 (Supplement_1), p.4630-4630

2019

Volltextzugriff (PDF)

Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen

British journal of clinical pharmacology, 2007-04, Vol.63 (4), p.469-476

2007

Volltextzugriff (PDF)

Effect of Food, an Antacid, and the H 2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Journal of clinical pharmacology, 2006-05, Vol.46 (5), p.549-558

2006

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin

Journal of clinical pharmacology, 2006-09, Vol.46 (9), p.981-990

2006

Volltextzugriff (PDF)

Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity

Journal of clinical pharmacology, 2007-11, Vol.47 (11), p.1398-1407

2007

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

The effect of food on the absorption and pharmacokinetics of rivaroxaban

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 : an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects

Serum markers detect the presence of liver fibrosis: A cohort study

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial

Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers

Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects

Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen

Effect of Food, an Antacid, and the H 2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin

Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity

Suchergebnisse filtern